Behçet’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Behçet's Disease Market Outlook

Thelansis’s “Behçet's Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Behçet's Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Behçet's Disease Overview

Behçet’s disease (BD) is an uncommon yet profoundly incapacitating vasculitis, primarily characterized by mucocutaneous manifestations, including orogenital ulcers and skin lesions. Notably, BD can affect various organ systems, such as the musculoskeletal, ocular, nervous, gastrointestinal, vascular, urogenital, and cardio-pulmonary systems, resulting in considerable morbidity and mortality. The diagnosis of BD is often delayed due to the variability and intermittency of symptoms, the necessity to exclude mimicking conditions, the absence of a specific blood test or disease marker, and a general lack of awareness about the disorder. The etiology of BD is unknown, with genetic predisposition potentially permitting specific infectious agents, particularly Streptococcus sanguis, or environmental factors to trigger inflammatory attacks resembling auto-inflammatory disorders through cross-reactions with oral mucosa antigens. The HLAB5101 antigen is implicated in 50-60% of BD cases, while NF-kB activation and abnormal cytokine levels (e.g., IL-6, TNF-a, IL-8, IL-12, IL-17, and IL-21) play a role in the pathogenesis of BD. A familial, autosomal dominant form of BD, associated with A20 haploinsufficiency, is linked to mutations in TNFAIP3(6q23.3). Although BD most commonly emerges in adults (mean age 30 years), pediatric cases have been reported, presenting with relapsing episodes of round oral aphthae, genital aphthae, and cutaneous features such as pseudo-folliculitis and erythema nodosum. Ocular disorders, including posterior uveitis and retinal vasculitis, occur in over 50% of BD patients. The differential diagnosis depends on the specific manifestations and conditions such as herpes ulcerations, spondylo-arthropathies, infectious uveitis, relapsing polychondritis, sarcoidosis, antiphospholipid syndrome, Takayasu arteritis, Crohn's disease, contagious meningoencephalitis, or multiple sclerosis may be considered. The primary treatment for BD involves anti-inflammatory steroids; however, corticosteroid dependence and relapses may ensue upon discontinuation. Concurrent administration of immunosuppressive drugs (e.g., azathioprine, cyclophosphamide, methotrexate, or mycophenolate mofetil) is also prescribed, although their therapeutic effects are delayed. Recently, Apremilast has gained approval for refractory oral ulceration in BD. Without treatment, BD prognosis is severe, posing risks such as ocular complications leading to potential blindness, lethal arterial rupture, large vessel thrombosis, and neurological symptoms that may result in encephalopathy or cerebral hypertension, leading to a loss of autonomy. Intensive care, close multidisciplinary follow-up, and tailored immunosuppressive treatment have demonstrated efficacy in reducing morbidity and mortality.

• In the United States, the prevalence of Behçet’s disease is reported to be 5.2 per 100,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: